JP5714203B2 - 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド - Google Patents

血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド Download PDF

Info

Publication number
JP5714203B2
JP5714203B2 JP2007557485A JP2007557485A JP5714203B2 JP 5714203 B2 JP5714203 B2 JP 5714203B2 JP 2007557485 A JP2007557485 A JP 2007557485A JP 2007557485 A JP2007557485 A JP 2007557485A JP 5714203 B2 JP5714203 B2 JP 5714203B2
Authority
JP
Japan
Prior art keywords
angiogenesis
defibrotide
pharmaceutical
preparation
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007557485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531646A (ja
JP2008531646A5 (enExample
Inventor
イアコベッリ，マッシモ
アイスナー，グンター
アイリス フェルロ，ローラ
アイリス フェルロ，ローラ
Original Assignee
ゲンチウム エスピーエー
ゲンチウム エスピーエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000336A external-priority patent/ITMI20050336A1/it
Application filed by ゲンチウム エスピーエー, ゲンチウム エスピーエー filed Critical ゲンチウム エスピーエー
Publication of JP2008531646A publication Critical patent/JP2008531646A/ja
Publication of JP2008531646A5 publication Critical patent/JP2008531646A5/ja
Application granted granted Critical
Publication of JP5714203B2 publication Critical patent/JP5714203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2007557485A 2005-03-03 2006-02-27 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド Expired - Fee Related JP5714203B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2005A000336 2005-03-03
IT000336A ITMI20050336A1 (it) 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale
US73140405P 2005-10-28 2005-10-28
US60/731,404 2005-10-28
PCT/EP2006/060304 WO2006094916A1 (en) 2005-03-03 2006-02-27 Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors

Publications (3)

Publication Number Publication Date
JP2008531646A JP2008531646A (ja) 2008-08-14
JP2008531646A5 JP2008531646A5 (enExample) 2009-04-02
JP5714203B2 true JP5714203B2 (ja) 2015-05-07

Family

ID=36572331

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007557486A Pending JP2008531647A (ja) 2005-03-03 2006-02-27 抗腫瘍作用を有する製剤
JP2007557485A Expired - Fee Related JP5714203B2 (ja) 2005-03-03 2006-02-27 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007557486A Pending JP2008531647A (ja) 2005-03-03 2006-02-27 抗腫瘍作用を有する製剤

Country Status (9)

Country Link
US (2) US20080194506A1 (enExample)
EP (2) EP1853277A1 (enExample)
JP (2) JP2008531647A (enExample)
KR (3) KR20070121001A (enExample)
AU (2) AU2006222044A1 (enExample)
CA (2) CA2598613A1 (enExample)
IL (3) IL185182A0 (enExample)
MX (2) MX2007010754A (enExample)
WO (2) WO2006094917A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
US8187897B2 (en) 2008-08-19 2012-05-29 International Business Machines Corporation Fabricating product chips and die with a feature pattern that contains information relating to the product chip
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
SG11202000952PA (en) 2017-08-03 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Formulations comprising a nucleic acid in a high concentration
MX2020010689A (es) 2018-04-12 2021-01-20 Jazz Pharmaceuticals Inc Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20230190783A1 (en) 2020-02-28 2023-06-22 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
JP2002512508A (ja) * 1997-05-30 2002-04-23 マクギル・ユニヴァーシティ Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
US7514414B2 (en) * 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.

Also Published As

Publication number Publication date
CA2598072A1 (en) 2006-09-14
US20080194506A1 (en) 2008-08-14
AU2006222044A1 (en) 2006-09-14
EP1855697A2 (en) 2007-11-21
AU2006222045A1 (en) 2006-09-14
IL185182A0 (en) 2008-01-20
JP2008531647A (ja) 2008-08-14
JP2008531646A (ja) 2008-08-14
IL185258A0 (en) 2008-02-09
WO2006094917A3 (en) 2006-12-14
EP1853277A1 (en) 2007-11-14
KR20070120953A (ko) 2007-12-26
US20080194507A1 (en) 2008-08-14
CA2598613A1 (en) 2006-09-14
WO2006094916A1 (en) 2006-09-14
IL185258A (en) 2010-12-30
WO2006094917A2 (en) 2006-09-14
WO2006094917A8 (en) 2008-01-31
IL185181A0 (en) 2008-01-20
KR20070121001A (ko) 2007-12-26
MX2007010754A (es) 2007-11-07
MX2007010407A (es) 2007-10-17
KR20070120954A (ko) 2007-12-26
AU2006222045B2 (en) 2011-10-20
CA2598072C (en) 2016-05-03

Similar Documents

Publication Publication Date Title
Hou et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis
Tanaka et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis
Hsieh et al. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers
Carlson et al. Cardiac macrophages adopt profibrotic/M2 phenotype in infarcted hearts: Role of urokinase plasminogen activator
Yoshida et al. p53-Induced inflammation exacerbates cardiac dysfunction during pressure overload
Armstrong et al. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
JP5714203B2 (ja) 血管新生依存性腫瘍を治療するためのデフィブロチドおよび／またはオリゴデオキシリボヌクレオチド
Feng et al. EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma
Xu et al. Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts
EP3158057B1 (en) Stem cell therapy in endometrial pathologies
Klein et al. Endothelial Caveolin-1 regulates the radiation response of epithelial prostate tumors
EA016653B1 (ru) Способы и композиции для ингибирования ангиогенеза
JP2024133372A (ja) 心不全の治療方法
Mukhopadhyay et al. Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells
Segaliny et al. Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells
Fu et al. Mild magnetothermal enhanced nanocatalytic immunotherapy for solid tumors by immune cell activation and intratumoral infiltration
Pidala et al. Ixazomib for treatment of refractory chronic graft-versus-host disease: a chronic GVHD consortium phase II trial
Ren et al. Migration-inducing gene-7 independently predicts poor prognosis of human osteosarcoma and is associated with vasculogenic mimicry
KR20200016163A (ko) 사멸화 세포 처리 대식 세포 유래 엑소좀을 포함하는 암 예방 또는 치료용 조성물
JP2012502934A (ja) 病理的血管新生を阻害する組成物
Chung et al. Antibody to interleukin-6 receptor inhibits in vivo growth of human colorectal carcinoma cell xenografts
WO2025140008A1 (zh) 重组蛋白ccl11在治疗恶性胸腔积液中的应用
Wang et al. Pigment epithelium-derived factor prevents endothelial dysfunction in early stage of hyperlipidemia by regulating endothelial fatty acid transport
Kang et al. EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma
Xiao et al. Layered double hydroxide-delivered si-NEAT1 inhibits breast cancer immune evasion and malignant progression by modulating the miR-141–3p/PD-L1 axis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120531

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120626

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120803

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150311

R150 Certificate of patent or registration of utility model

Ref document number: 5714203

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees